Evotec SE Stock: Horizon Restructuring Plan Sets Stage for 2026 Turnaround Amid Upcoming Earnings

Evotec SE (ISIN: DE0005664809), the German drug discovery and biologics firm listed on Nasdaq (EVO) and Frankfurt (EVT), nears its Q4 and full-year 2025 earnings release on April 8, 2026. Investors watch the Horizon plan's progress, targeting €75M cost savings by 2027 despite €100M restructuring costs, with biologics growth offsetting discovery challenges.

Evotec SE stands at a pivotal moment as it prepares to report financial results for the fourth quarter and full-year 2025 on April 8, 2026. The upcoming webcast offers North American investors a clear view into the progress of its Horizon restructuring plan, which aims to deliver sustainable profitability through cost discipline and biologics expansion.

As of: 02.04.2026

By Dr. Elena Voss, Senior Financial Editor at NorthStar Market Insights: Evotec SE exemplifies the challenges and opportunities in contract research and biologics services amid biotech sector transformations.

Company Overview and Core Business Model

Evotec SE, headquartered in Hamburg, Germany, operates as a life sciences company focused on drug discovery and development services. It provides integrated solutions to pharmaceutical and biotechnology partners worldwide, spanning from target identification to clinical supply.

The company divides its operations into two primary segments: Discovery and Just Evotec Biologics (JEB). Discovery involves early-stage research, while JEB handles biologics manufacturing and development, an area showing robust growth potential.

Listed on Nasdaq as EVO and Frankfurt Prime Standard as EVT, with ISIN DE0005664809, Evotec trades primarily in euros on the German exchange. This dual listing facilitates access for North American investors seeking exposure to European biotech services.

Evotec's asset-light model in biologics emphasizes scalability, allowing it to capitalize on demand for outsourced development without heavy capital investments. This structure positions the firm well in a sector where big pharma increasingly partners with specialized providers.

Horizon Restructuring: The Path to Profitability

The Horizon plan represents Evotec's strategic overhaul, targeting run-rate savings of around €75 million by the end of 2027. This initiative follows prior cost actions and focuses on streamlining operations across its global footprint.

Key elements include reducing sites from 19 to 10, enhancing commercial execution in Discovery, and improving earnings quality in Biologics. Management anticipates €100 million in restructuring costs through 2028, framing 2026 as a transition year.

For 2026, Evotec guides group revenue between €700 million and €780 million, with adjusted EBITDA from €0 to €40 million on the Frankfurt exchange in euros. This reflects upfront restructuring pressures but sets the stage for margin expansion.

By 2028, the company eyes a revenue compound annual growth rate of 8-12% and adjusted EBITDA margins exceeding 20%. Achieving this hinges on synchronized improvements in both segments.

Segment Performance: Biologics Strength vs. Discovery Challenges

Just Evotec Biologics demonstrated resilience in 2025, achieving approximately 40% growth and adjusted EBITDA near €53 million. A €65 million licensing fee from Sandoz, part of a €350 million upfront deal with milestones, bolstered this performance.

In contrast, the Discovery segment reported adjusted EBITDA around -€12 million in 2025, highlighting operational pressures. Horizon aims to address this through footprint optimization and sharper focus.

Biologics' high-margin, asset-light approach provides a buffer, potentially carrying the group through restructuring. Investors should monitor if this growth sustains amid sector demand for biologics outsourcing.

North American pharma giants increasingly rely on such partners for speed and expertise, aligning Evotec's model with U.S. market trends in antibody and protein therapeutics.

Recent Leadership Changes and Strategic Hires

On April 1, 2026, Evotec appointed Dr. Ashiq H. Khan as EVP Global Head and Chief Commercial Officer. Dr. Khan brings over 15 years of experience in biotech, CRO, and AI-driven platforms, with a track record of securing over $7 billion in deals across U.S., EU, and APAC.

This hire underscores Evotec's emphasis on commercial momentum, particularly in expanding partnerships. His transcontinental expertise could enhance deal flow in North American markets.

Combined with the Horizon plan, such moves signal proactive management. Investors may view this as a catalyst for improved revenue quality post-restructuring.

Relevance for North American Investors

North American investors gain exposure to Evotec via Nasdaq (EVO), bridging U.S. biotech demand with European service efficiency. The firm's partnerships with major pharma align with trends in outsourced R&D.

Upcoming earnings on April 8, 2026, at 8:00 am EDT provide timely insights. Positive updates on Horizon savings or biologics deals could drive interest amid U.S. sector volatility.

Evotec's scale in biologics manufacturing complements North American firms scaling therapies. Its SDAX index inclusion offers a pure-play on drug services growth.

For U.S. portfolios, Evotec adds diversification into high-growth services, less correlated with pure biotech product risks.

Risks and Key Open Questions

Restructuring execution poses risks, including potential delays in site consolidations or cost overruns beyond €100 million. Any slippage could pressure 2026 EBITDA guidance.

Discovery's turnaround remains uncertain; sustained losses might offset biologics gains. Investors should watch quarterly progress toward €75 million savings.

Biotech sector headwinds, such as funding constraints or partner pipeline delays, could impact deal flow. Macroeconomic factors in Europe add currency exposure for USD investors.

North American watchers should track the August 13, 2026, Q2 results for early Horizon signals. Delivering on 2028 margin goals will define long-term value.

Evotec's path involves balancing transformation costs with growth levers. Prudent monitoring of execution metrics remains essential.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.